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Editorial Comment 
Pathophysiologic Relevance of 
Neurohumoral Measurements in 
Chronic Heart Failure* 
THIERRY H. LEJEMTEL, MD 
Bronx. New York 
The activation of the sympathetic nervous and renin-angio•
tensin systems and the release of vasopressin have been 
well documented in normal subjects after acute volume de•
pletion. However, the utility and potential deleterious ef•
fects, the stimulation sequence and the relative importance 
of the different neuroendocrine mechanisms in patients with 
chronic heart failure are not as clearly delineated for several 
reasons. The major difficulty is that the clinical syndrome 
of congestive heart failure is a dynamic and poorly under•
stood process. Although clinicians may accurately stage a 
solid tumor or assess the extent of an infectious disease, 
there are no obvious markers for the severity of heart failure 
or the rate of progression of the underlying myocardial dys•
function. For a given patient with heart failure, there is a 
poor correlation between symptoms. exercise tolerance. 
measured left ventricular function and prognosis. 
As a result, an isolated "snapshot" measurement of a 
neurohumoral response (that is, norepinephrine, renin or 
vasopressin levels) cannot be matched with a precise defi•
nition or stage of the heart failure disease process. In ad•
dition, plasma levels of circulating hormones are grossly 
inadequate to account for the effect of the substances at the 
tissue or end organ level. To further complicate the issue, 
neurohumoral measurements are influenced by fluid intake, 
diet, activity, concurrent medical therapy and differences 
in blood sampling techniques and hormonal assays. More•
over, the physiologic consequences of these neuroendocrine 
systems are extremely complex, acting at multiple receptor 
sites and interacting with other vasoactive substances such 
as prostaglandins and atrial-natriuretic factor (1-3). 
Vasopressin in congestive heart failure. In this issue 
of the Journal, Creager and associates (4) describe their use 
of a specific competitive antagonist of the vascular actions 
of vasopressin to provide evidence that high levels of va-
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sopressin may contribute to the increased systemic vascular 
resistance seen in patients with chronic heart failure. As the 
precise determination of plasma vasopressin levels by ra•
dioimmunoassay has become available, several investiga•
tors (5-10) have reported that patients with and without 
hyponatremia and congestive heart failure have elevated 
vasopressin levels compared with normal subjects. Because 
vasopressin, even at moderately increased levels. can stim•
ulate the calcium-dependent vascular receptors, it has been 
suggested (11-14) that, in some patients, vasopressin may 
further augment the already heightened vascular tone. The 
data of Creager et al. (4) appear to confirm this hypothesis 
and to differ with the results of an experimental study (15) 
in which the vasopressin antagonist was used in a model of 
high output cardiac failure. In that study. despite a fourfold 
increase in vasopressin levels at baseline. no significant 
change in arterial pressure, cardiac output or peripheral vas•
cular resistance occurred after administration of the antagonist. 
Hemodynamic actions of vasopressin and results of 
withdrawal of its vasoconstrictor effect. These discrep•
ancies are further confounded by the response of the five 
patients with "normal" levels of vasopressin in the study 
by Creager et al. (4). In these patients the vasopressin an•
tagonist caused a rise in systemic vascular resistance. This 
may be partly explained by a further examination of the 
hemodynamic actions of vasopressin. At physiologic levels, 
stimulation of vasopressin in normal subjects causes a direct 
vasoconstrictor effect that, in tum, stimulates the barore•
ceptor reflex to lower cardiac output. As a result of these 
opposite maneuvers, systemic arterial pressure remains un•
changed. Thus, in patients with heart failure but intact baro•
receptors, the hemodynamic response to a vasopressin an•
tagonist will be determined by the reflexive response of 
cardiac output and peripheral resistance to a sudden drop in 
arterial pressure caused by the loss of vasopressin-induced 
vascular tone. It may be argued that compensatory vasocon•
strictor mechanisms supervene to support the blood pressure 
and an increase in systemic vascular resistance will ensue, 
as observed by Creager et al. (4). In contrast, patients with 
more severe heart failure and higher levels of circulating 
norepinephrine, in whom the baroreceptor reflex has been 
shown to be impaired, may also have concomitantly higher 
levels of vasopressin (16. I 7). Withdrawal of the vasocon•
strictor effect of vasopressin in these patients as a result of 
the antagonist will lead to a pronounced fall in cardiac 
afterload, and hence a higher cardiac output, in the absence 
of baroreceptor reflex-mediated vasoconstriction (18, I 9). 
Alternatively, the vasopressin antagonist could be a partial 
agonist at low levels of plasma vasopressin and a full an•
tagonist at higher levels of the hormone. Indeed, it would 
be useful to know the intrinsic actions of the specific an•
tagonist in the normal circulation under various circumstances. 
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. Therapeutic implications. Finally, when considering 
the potential therapeutic applications of a vasodilator agent 
in the treatment of chronic heart failure, knowledge of which 
vascular beds are specifically vasodilated may be more im•
portant than knowledge of the short-term effects of the agent 
on ventricular performance and systemic vascular resist•
ance, For instance, although hydralazine effects a greater 
short-term increase in cardiac output and fall in systemic 
vascular resistance than does captopril, captopril vasodilates 
predominantly the coronary and renal beds and produces 
greater long-term symptomatic improvement. Angiotensin 
II is far more potent than vasopressin as a renovascular 
constrictor; thus, vasopressin antagonists may prove to be 
of lesser therapeutic interest than angiotensin-converting en•
zyme inhibitors (13,20-22). 
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